The race to find a safe and effective vaccine against COVID-19 entered a new phase this week as both Moderna, Inc.and Pfizer Inc. began enrolling volunteers onto their pivotal late-stage studies in the US.
There remains a chance that both the Moderna and National Institutes of Health (NIH) candidate and Pfizer/BioNTech’s offerings will falter...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
